A randomized controlled clinical study of rosuvastatin combined with carvedilol in the prevention of complications of portal hypertension due to cirrhosis guided by HVPG

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037306

Enrollment

Unknown

Registered

2020-08-27

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

A:Rosuvastatin combined with carvedilol

B:carvedilol

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Fully understand the purpose, nature, method and possible adverse reactions of the study, volunteer to be a subject, and sign the informed consent form (ICF) before the start of any research procedure, and ensure that I will participate in any procedure; 2. Age: 18-75 years old; 3. Diagnosis of liver cirrhosis (both clinical and pathological); 4. The results of electronic gastroscopy meet the high-risk criteria of gastroesophageal varices (HRV), defined as moderate or severe gastroesophageal varices (gov) or varices of any size with red sign; 5. HVPG > 12 mm Hg; 6. Sign informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Contraindications of electronic gastroscopy; 2. Contraindications of carvedilol or statins, taking nsbb and statins in the past 6 months; 3. CTP grade C; 4. History of hepatocellular carcinoma; 5. Portal vein thrombosis or cavernous change, hepatic vein outflow tract obstruction; 6. Pregnant or lactating women and women planning to become pregnant during the study period; 7. Epilepsy patients with mental history or uncontrollable; 8. Uncontrollable diabetes mellitus; 9. Bronchial asthma; 10. There are serious basic diseases, including chronic respiratory failure, circulatory failure and renal failure; 11. Other situations that the researchers considered not suitable for the study; 12. The basic causes were not controlled, such as HBV and HCV detection lower than the normal upper limit, less than 6 months; 13. History of bleeding or endoscopic ligation; 14. Chronic and acute liver failure; 15. After surgical portosystemic shunt or tips.

Design outcomes

Primary

Measure	Time frame
Hepatic vein pressure gradient;	—

Countries

China

Contacts

Public ContactQingchun Fu

Shanghai Public Health Clinical Center

qcfu85@163.com+86 13701826468

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026